The Maximum-Tolerated Dose and Pharmacokinetics of ISFP10 a Novel Inhibitor of Fungal Phosphoglucomutase (PGM)

BackgroundThe newly identified small molecule ISFP10 has demonstrated the ability to inhibit fungal phosphoglucomutases (PGM), leading to decreased fungal growth and survival. Exhibiting 50 times greater selectivity for fungal PGM compared to the human homolog, ISFP10 shows promise as a broad-spectrum antifungal and a candidate for preliminary testing in rodent models of fungal infections, including Pneumocystis pneumonia (PCP). In preparation for targeted and relevant administration of the drug in fungal mouse models of infection, the current study describes the maximum-tolerated-dose (MTD) and pharmacokinetics (PK) of ISFP10 in mice. MethodsFor the MTD study, 24 C57BL/6 mice were randomly distributed into 6 groups (2M/2F per group): Placebo (vehicle; 10% DMSO with 90% of 0.5% methylcellulose in 0.9% NaCl) at various doses (12.5, 25, 50, 100, 200 mg/kg), were administered twice daily by intraperitoneally (IP) for 7 consecutive days. For the PK study, 108 mice were administered either vehicle or ISFP10 in single-dose intraperitoneal (IP) injections twice daily for 7 consecutive days at concentrations of 0, 12.5, 25, 50, and 100 mg/kg. Pharmacokinetics were assessed in plasma, and epithelial lining fluid (ELF). Analysis of this test compound was performed using LC-MS/MS for PK evaluation on blood samples drawn from mice at multiple time points. ResultsIP administered, ISFP10 did not produce significant changes in body weight, food consumption or adverse events in the MTD up to 100 mg/kg dosing. The plasma PK study demonstrated Tmax values ranging from 2 to 8 h. Non-compartmental analysis (NCA) yielded elimination half-life values, t1/2, of 4.39 and 5.31 h for the 12.5 and 50 mg/kg dose groups. Concentration dependent peak-blood concentration (Cmax) at the dosing and length tested ranged from 3.450-5.140 ug/ml. ConclusionsIn conclusion, ISFP10, administered intraperitoneally to mice twice daily at doses up to 100 mg/kg, exhibited no inherent safety concerns based on the analyzed parameters. Pharmacokinetic analysis revealed slow absorption and distribution kinetics, with plasma Tmax values ranging from 2 to 8 hours and elimination half-lives of approximately 4-5 hours at lower doses. These data support broader in vivo testing of the inhibitor as potential novel antifungal in fungal diseases including PCP.